# US 2025/0082792 A1 · Zwitterionic metal chelators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082792 A1
- Document ID: US20250082792A1
- Status: Published application
- Kind: A1
- Application number: 18/640,169
- Filed: 2024-04-19
- Published: 2025-03-13
- Earliest claimed: 2023-09-12
- Assignees: Curadel Surgical Innovations, Inc.
- Applicants: Curadel Surgical Innovations, Inc.
- Inventors: John V. Frangioni; Wolfgang Maison
- Web page: https://patentgrep.com/patent/US20250082792A1

## CPC

- A61K 51/0482: {chelates from cyclic ligands, e.g. DOTA}
- A61B 6/037: {Emission tomography}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K 51/0402: {carboxylic acid carriers, fatty acids (amino acids A61K51/0406)}
- A61K 51/0455: {having six-membered rings with one nitrogen as the only ring hetero atom}
- A61K 51/0478: {complexes from non-cyclic ligands, e.g. EDTA, MAG3}
- A61K 51/0497: {conjugates with a carrier being an organic compounds}
- A61K 51/082: {the peptide being a RGD-containing peptide}
- A61K 51/083: {the peptide being octreotide or a somatostatin-receptor-binding peptide}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 2121/00: Preparations for use in therapy
- A61K 2123/00: Preparations for testing in vivo
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

The present invention relates to zwitterionic metal chelators and their use as imaging, diagnostic, chemical processing, and treatment agents. These zwitterionic metal chelators have desirable properties that maximize solubility in aqueous environments, minimize non-specific interactions, and retain the ability to target thus resulting in an improved performance in a variety of medical, agricultural, and chemical processes. In in vivo and medical applications, zwitterionic metal chelators improve the signal-to-background ratio and therapeutic window as compared to other metal chelators while retaining high stability.

## Claims

### Claim 1

A zwitterionic metal chelator complex comprising a metal chelator having one or more zwitterionic groups and a metal or metal isotope selected from the group consisting of a radionuclide, a label, a paramagnetic metal and a heavy metal,
wherein the metal chelator is a derivative of DOTA having the formula:
wherein ZWI represents a zwitterionic group; each instance of W and Y independently represent a linking group, and each instance of X represents a reactive group;
and with the proviso that the metal chelator is not:

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The zwitterionic metal chelator complex according to claim 1, further comprising one or more targeting vectors; wherein the one or more targeting vectors are cRGD, KUE, PSMA-617, FAPI, octreotide, bombesin, or a homo- or hetero-dimer formed from their combination.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The zwitterionic metal chelator complex according to claim 1, wherein the metal chelator is a derivative of DOTA and the metal or metal isotope is Pb Zr, Cu, Ga, In, Y, Gd, Lu, Ac or Tb.

### Claim at position 6

6-16. (canceled)

### Claim 17 (depends on 1)

An imaging agent comprising a zwitterionic metal chelator complex according to claim 1.

### Claim 18 (depends on 17)

A method of imaging cells, tissues, or organs, the method comprising:
(a) contacting cells with an imaging agent according to claim 17; and
(b) imaging the cells, tissues, or organs using positron emission tomography (PET), single-photon emission computerized tomography (SPECT), or magnetic resonance imaging (MRI).

### Claim at position 9

19-22. (canceled)

### Claim 23 (depends on 1)

A therapeutic agent comprising a zwitterionic metal chelator complex according to claim 1 and a pharmaceutically acceptable carrier or excipient.

### Claim 24 (depends on 23)

A method of treating a cancerous condition in a subject in need thereof, the method comprising:
contacting cancer cells in the subject with an effective amount of a therapeutic agent according to claim 23,
wherein the metal atom complexed to the zwitterionic metal chelator is:
a radioactive metal isotope known to emit ionizing radiation that results in the death of cells that take up the analogs;
or a non-radioactive metal that is capable of releasing cytotoxic radiation upon irradiation with alpha emission, beta emission, neutron capture, or a combination thereof.

### Claim at position 12

25-46. (canceled)

### Claim 47 (depends on 23)

A method of treating a cancer by administering an effective amount of a therapeutic agent according to claim 23, wherein the method comprises a step to diagnose the cancer and a step of administering the therapeutic agent to a subject determined to be in need thereof,
wherein the step to diagnose the cancer comprises:
contacting cells, tissues or organs of a subject with an imaging agent,
imaging the cells, tissues, or organs of the subject using positron emission tomography (PET), single-photon emission computerized tomography (SPECT), or magnetic resonance imaging (MRI), and
diagnosing the cancer in the cells tissues, or organs of the subject based on imaging data collected;
and wherein the metal atom complexed to the zwitterionic metal chelator is:
a radioactive metal isotope known to emit ionizing radiation that results in the death of cells that take up the analogs;
or a non-radioactive metal that is capable of releasing cytotoxic radiation upon irradiation with alpha emission, beta emission, neutron capture, or a combination thereof.
